We are excited to announce that NGN-401 gene therapy for Rett syndrome was one of only three CBER programs selected for inclusion in the FDA’s START Pilot Program. NGN-401 was selected based on potential for clinical benefits and clinical development program readiness. Through the START Program, we will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401’s development. Learn more here: https://bit.ly/3V7DLdd
Fantastic news. Congrats to the team at Neurogene and the potential this will have on patients.
Great partnership!!!
Congratulations!
Great work!
Congratulations Rachel McMinn, Stuart Cobb, Christine Mikail, Andrew E. Mulberg, MD, FAAP and everyone at Neurogene on this amazing achievement! Godspeed!